Financial Performance - Revenue for the quarter ended March 31, 2024, increased by $366,742 to $823,800 compared to $457,058 in the same period in 2023, attributed to customer base expansion[174] - Gross profit for the quarter ended March 31, 2024, was $178,489, a significant increase from $33,049 in the same period in 2023[172] - The company reported a net loss of $2,986,765 for the quarter ended March 31, 2024, compared to a net loss of $6,352,017 in the same period in 2023[172] - Revenue from sales of goods increased by $1,570,220, reaching $2,383,957 for the nine months ended March 31, 2024, compared to the same period in 2023[175] - Gross profit increased by $332,975 to $610,068 for the nine months ended March 31, 2024, due to revenue growth from an expanded customer base[180] - Net loss attributable to INBS decreased by $600,287 to $7,372,512 for the nine months ended March 31, 2024, primarily due to prior goodwill impairment charges[202] Operating Expenses - The total operating expenses for the quarter ended March 31, 2024, were $3,216,066, a decrease from $6,694,128 in the same period in 2023[172] - Selling, general and administrative expenses increased by $993,473 to $6,587,934 for the nine months ended March 31, 2024, primarily due to marketing and compliance costs[186] - Development and regulatory approval expenses increased by $543,349 to $923,712 for the nine months ended March 31, 2024, driven by in-house R&D staff costs[189] - Interest expenses decreased by $51,367 to $112,590 for the nine months ended March 31, 2024, due to the conversion of convertible notes into common shares[193] Cash Position - As of March 31, 2024, the company had a cash balance of $9.40 million after raising approximately $10.76 million through a warrant inducement transaction and a private placement offering[171] - Cash and cash equivalents as of March 31, 2024, were $9,397,523, with working capital of $5,814,284[204] - The company expects its cash and cash equivalents may be insufficient to fund its current operating plan for at least the next twelve months[205] Customer and Market Development - The company secured 26 new customer accounts during the quarter, representing a combined headcount of approximately 16,779 employees[171] - The company announced a partnership with Cliantha Research to conduct pharmacokinetic studies as part of its FDA 510(k) clinical studies plan, aiming for a product launch in the U.S. in 2025[171] - A new European patent for the DSR-Plus Cartridge Reader was granted, effective in 17 European countries[171] Risks and Uncertainties - The company operates in a competitive environment with ongoing risks and uncertainties that may affect future results[161] - Unrealized foreign currency translation loss increased by $66,239 to $144,026 for the quarter ended March 31, 2024, compared to the same period in 2023[199] Equity Interest - The company has a 50% equity interest in BiosensX (North America) Inc., which has a separate technology license agreement for glucose/diabetes management in North America[168] Cost of Revenue - Cost of revenue increased by $1,237,245 to $1,773,889 for the nine months ended March 31, 2024, driven by the increase in revenue from the acquisition of IFP[177]

Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024 Cash and cash equivalents as of March 31, 2024, was $9.40 million Commenced FDA 510(k) clinical studies plan with Cliantha Research and remains on track for planned submission by the end of 2024 and planned entry into the US in 2025 Secured 26 new customer accounts throughout the quarter, representing a combined headcount of approximately 16,779 employees NEW YORK, May 08, 2024 (GLOBE NEWSWIRE ...

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening of the intellectual property portfolio of its wholly owned subsidiary, Intelligent Fingerprinting Limited, with the grant of a new European patent with unitary effect for its ground-breaking DSR-Plus Cartridge Reader. This latest achievement follows the successful protect ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 ...

Revenue and Profit - Revenue for the year ended June 30, 2023, was $1,256,872, an increase from $0 in the previous year, attributed to the acquisition of Intelligent Fingerprinting Limited and the launch of fingerprint drug testing in the APAC region [317]. - Gross profit for the same period was $326,668, up from $0, primarily due to the acquisition of Intelligent Fingerprinting Limited [320]. - Government support income rose to $737,628 from $437,146, an increase of $300,482, mainly due to qualifying research and development expenditures [322]. - Fair value gain on revaluation of financial instruments increased by $2,154,365 to $2,154,365 from $0 for the year ended June 30, 2023 [332]. - Interest income decreased by $4,750 to $9,676 from $14,426 for the year ended June 30, 2023, due to lower bank balance [333]. - Unrealized foreign currency translation gain increased by $339,514 to a gain of $212,639 from a loss of $126,875 for the year ended June 30, 2023 [334]. - Net loss attributable to INBS increased by $2,325,669 to $10,631,720 from $8,306,051 for the year ended June 30, 2023, primarily driven by impairment of goodwill of $4,158,670 [335]. Expenses - Selling, general and administrative expenses increased by $3,106,600 to $8,026,703, largely due to the addition of approximately 32 staff from the acquisition of Intelligent Fingerprinting Limited [324]. - Development and regulatory expenses decreased by $3,346,495 to $507,424, primarily due to the expensing of a prepaid R&D contribution in the previous year [326]. - Depreciation and amortization expenses were $966,732, an increase from $0, due to the amortization of acquired intangibles from the acquisition [328]. - Goodwill impairment expenses were $4,158,670, reflecting the impact of the acquisition of Intelligent Fingerprinting Limited [329]. - Interest expense increased to $223,534 from $7,539, attributed to interest on convertible notes post-acquisition [330]. Cash and Working Capital - As of June 30, 2023, the company had $1,537,244 in cash and cash equivalents and a working capital deficit of $2,021,124 [337]. - The company expects its cash and cash equivalents will be insufficient to fund its current operating plan for at least the next twelve months [338]. Grants and Deferred Income - The total grant value of $4.7 million was recognized as both a grant receivable and deferred grant income, with payments of $1.4 million and $2.1 million received during the years ended June 30, 2023 and 2022, respectively [348]. - A total of $127,944 and $51,258 deferred grant income was recognized within other income during the years ended June 30, 2023, and 2022, respectively [350]. Strategic Initiatives - The company intends to submit a 510(k) pre-market notification for its Intelligent Fingerprinting Drug Screening Cartridge as part of its U.S. expansion strategy [315]. - The company has expanded its customer base by entering into sales contracts with various firms, enhancing its market presence [316]. Other Information - The company has no off-balance sheet arrangements or relationships with unconsolidated entities [341]. - The company recognized an impairment charge of $4.2 million in the IFPG segment related to goodwill associated with the IFP Acquisition [354].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 (Sta ...

Acquisition and Expansion - The company completed the acquisition of Intelligent Fingerprinting Limited (IFP) on October 4, 2022, expanding its portfolio of rapid, non-invasive diagnostic testing technologies[168]. - The IFP acquisition involved issuing 2,963,091 shares of common stock and 2,363,003 shares of Series C Convertible Preferred Stock as consideration[169]. - IFP expanded its customer base by entering sales contracts with several UK companies, including Glass Systems and Eastern Airways[180]. - The company aims to increase market share in the UK and West Europe while commencing distribution in the Asia region and pursuing FDA regulatory approval for the US market[175]. Financial Performance - Revenue from sales of goods increased from $0 to $356,679 for the quarter ended December 31, 2022, compared to the same period in 2021, due to the acquisition of Intelligent Fingerprinting Limited (IFP) during the current quarter[199]. - Gross profit for the quarter ended December 31, 2022, was $244,044, with total operating expenses of $2,644,636, resulting in a loss from operations of $2,130,967[198]. - The net loss for the quarter ended December 31, 2022, was $427,071, compared to a net loss of $3,463,823 for the same period in 2021[198]. - The total comprehensive loss for the six months ended December 31, 2022, was $1,415,111, compared to a comprehensive loss of $4,961,790 for the same period in 2021[198]. - Cash and cash equivalents as of December 31, 2022, were $2,911,682, with working capital of $1,563,530[226]. - The company expects its cash and cash equivalents will be insufficient to fund its current operating plan for at least the next twelve months[227]. Research and Development - The company is developing a Saliva Glucose Biosensor (SGB) to replace invasive blood glucose monitoring for diabetic patients, with ongoing clinical studies involving 40 adult subjects[174]. - The Saliva Glucose Test (SGT) is expected to substitute invasive blood glucose monitoring for diabetic patients, utilizing a non-invasive method to measure glucose levels in saliva[188]. - The Biosensor Platform Technology allows for the detection of multiple biological analytes, with the potential to develop tests for cancer biomarkers and hormones[197]. - The SGB (Saliva Glucose Biosensor) can detect glucose in saliva at concentrations between 8 and 200 µM, exhibiting sensitivity 100 times lower than blood glucose levels[190]. - The company has completed the development of an intermediate device that communicates with smart devices, enhancing the functionality of the SGB[194]. - The company is developing an R&D and manufacturing facility at the University of Newcastle, Australia, with construction expected to start in Q2 2023[180]. Stock and Shareholder Information - A reverse stock split at a ratio of 1-for-20 became effective on February 9, 2023, reducing the number of outstanding shares from approximately 18.3 million to about 916,265[178]. - The company has reserved up to 1,649,273 shares of Series C Preferred Stock for potential future issuance related to the IFP acquisition and employee stock options[170]. - The weighted average shares outstanding for the quarter ended December 31, 2022, was 908,283, compared to 744,126 for the same period in 2021[198]. Government Support and Expenses - The company reported government support income of $269,625 for the quarter ended December 31, 2022, compared to $177,791 for the same period in 2021[198]. - General and administrative expenses increased by $1,242,045 to $2,245,289 for the quarter ended December 31, 2022, compared to $1,003,244 in the same period in 2021, largely due to the acquisition of IFP[207]. - Development and regulatory expenses decreased by $2,639,991 to $1,191 for the quarter ended December 31, 2022, compared to $2,641,182 in the same period in 2021[210]. - Government support income in the IFPG and SGBP segments increased by $91,834 to $269,625 for the quarter ended December 31, 2022, compared to $177,791 in the same period in 2021[203]. Other Financial Metrics - The outstanding fair value of convertible notes as of December 31, 2022, was $523,703, with an interest rate of 17% per annum[230]. - Unrealized foreign currency translation gain increased by $354,242 to $361,597 for the quarter ended December 31, 2022, compared to $7,355 in the same period in 2021[221]. - Net loss attributable to INBS decreased by $3,039,398 to $420,600 for the quarter ended December 31, 2022, compared to $3,459,998 in the same period in 2021[223].

Intelligent Bio Solutions Inc. (NASDAQ:INBS) Q1 2023 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Harry Simeonidis - Chairman and CEO Spiro Sakiris - Chief Financial Officer Philip Hand - Executive Chairman, Intelligent Fingerprinting Limited Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the Intelligent Bio Solutions Inc. First Quarter 2023 Earnings Conference Call. Currently, all participants are in listen-only mode. A question-and-an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 ...